Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAGNAR phase II study of tarlatamab alone or with FOLFIRI in advanced digestive neuroendocrine carcinoma
2024-514327-42-00Phase 2Completed
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Dec 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of tarlatamab in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) and neuroendocrine carcinoma of unknown primary origin (CUP-NEC) (2 arms), sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoints: Progression-free survival rate and 12-month overall survival rate. Started Dec 2025; status: completed.
02
Drugs
tarlatamab
03
Conditions
gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)neuroendocrine carcinoma of unknown primary origin (CUP-NEC)
Beyond the preview
Go deeper on 2024-514327-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514327-42-00.